Notícias

Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy.

Bio-Techne Corp. (NASDAQ:TECH) is one of the 9 Stocks Winning by Double Digits. Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors gobbled up shares following news that it is merging with pharmaceutical giant Merck for $11.3 billion. In a statement, Bio-Techne Corp. (NASDAQ:TECH) said […]

Find insight on Merck KGaA’s deal to buy Bio-Techne, GSK and more in the latest Market Talks covering the Health Care sector.

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed the commercial strategy for one of the company’s largest business franchises. Mr. Sims will lead the commercial strategy and […] The post Candel Therapeutics Designates Mark Sims as CCO appeared first on ExecEdge.

Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index gaining 1.7% and the S

US stocks (^DJI, ^IXIC, ^GSPC) search for direction ahead of Thursday's session close, while Micron Technology (MU) holds onto gains following its massive earnings beat yesterday. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the day's market moves, Big Tech stocks, and how Micron's stock gains may be impacting Apple (AAPL).

The proposed acquisition will be the company’s biggest deal in more than a decade and represents an early move by new CEO Kai Beckmann to bolster the business.

The Dow Jones Industrial Average and S&P 500 were up in late-morning trading Thursday, while the Nas

The S&P 500 index was up about 0.3%, while the Nasdaq Composite fell 0.4%.

The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.

Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Bio-Techne (TECH) said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with

Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]

Shares of Bio-Techne surged before the opening bell on Thursday after Germany’s Merck KGaA announced it has agreed to purchase the company for $11.3 billion. Bio-Techne stock jumped 21% to $70.95 in premarket trading on Thursday. Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.

Germany’s Merck KGaA has announced a major acquisition agreement to buy U. S.

June 25 () - Merck KGaA has agreed to ‌acquire biotech firm Bio-Techne ‌Corp for $11.3 billion, the German science ​and healthcare firm said in a statement on Thursday.

Merck KGaA offered $73 a share in cash for Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier’s closing price Wednesday.

7.50am: 3i reveals slower growth for Action 3i Group said its largest portfolio company, Action, remains on track for a good second quarter despite like-for-like sales growth slowing. Ahead of its annual general meeting on Thursday, the FTSE 100-listed private equity investor said European...

Merck & Co., Inc. (NYSE:MRK) is included among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors. On June 24, CICC initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating. It also set a $138 price target on the stock. Merck also provided an updated outlook during its first-quarter 2026 earnings call. […]

AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of a slowdown.

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Merck & Co., Inc. (NYSE:MRK) is one of the best weight loss drugs on this list. TheFly reported on June 18 that MRK announced that the U.S. Food and Drug Administration (FDA) granted an expanded approval for Capvaxive, extending its […]

Pre-Market Stock Futures: Futures are trading higher this morning, but if you’ve ever heard the old saying, “when the chips are down”, that was the poster child phrase for Tuesday’s session, as technology stocks, and specifically the semiconductor stocks, followed a worldwide sell-off that initially began in Korea and carried around the globe. When ... Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Soft

In June 2026, Merck reported positive Phase 3 results for its anti-TL1A antibody tulisokibart in moderately to severely active ulcerative colitis, alongside recent US FDA approvals expanding KEYTRUDA–WELIREG use in kidney cancer and CAPVAXIVE’s indication to higher-risk children and adolescents. Together, these updates highlight Merck’s push to broaden its portfolio beyond oncology by advancing late-stage immunology assets and deepening its vaccines and cancer franchises. We’ll now examine...

Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 1.5% and the St

We just covered the 10 Stocks That Will 10X According to Social Media. Tempus AI (NASDAQ:TEM) ranks #7 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 33 Tempus AI (NASDAQ:TEM) runs cancer diagnostic tests and sells the resulting data and AI tools to pharmaceutical companies and research institutions. […]

Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.

MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.